Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.
Department of Molecular, Cellular, and Developmental Biology, and Neuroscience Research Institute, University of California, Santa Barbara, California 93106-9610, USA.
Journal Article: Molecular Cancer Therapeutics (impact factor: 4.95). 10/2010; 9(10):2700-13. DOI: 10.1158/1535-7163.MCT-10-0645
Abstract
Source: PubMed
Comments on this publication
ResearchGate members can add comments. Sign up now and post your comment!
Similar publications
Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Molecular cancer therapeutics. 9(10):2689-99.
Antibody-DM1 conjugates as cancer therapeutics.
Cancer letters. 307(2):113-8.
Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.
Bioconjugate chemistry. 22(4):728-35.
Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells.
Molecular cancer therapeutics. 10(11):2062-71.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

